Spyre Therapeutics (SYRE) Projected to Post Earnings on Tuesday

Spyre Therapeutics (NASDAQ:SYRE) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Spyre Therapeutics to announce earnings of ($0.7807) per share for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.40. On average, analysts expect Spyre Therapeutics to post ($2.71) EPS for the current fiscal year and ($3.67) EPS for the next fiscal year.

Spyre Therapeutics Trading Up 2.9%

Shares of SYRE opened at $92.91 on Tuesday. The company has a market capitalization of $9.47 billion, a price-to-earnings ratio of -47.65 and a beta of 3.10. The stock has a 50 day moving average of $90.75 and a 200 day moving average of $71.50. Spyre Therapeutics has a 12 month low of $21.15 and a 12 month high of $110.18.

Insider Transactions at Spyre Therapeutics

In other news, CFO Scott L. Burrows sold 7,500 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $91.83, for a total transaction of $688,725.00. Following the transaction, the chief financial officer owned 79,762 shares of the company’s stock, valued at $7,324,544.46. This represents a 8.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Heidy King-Jones sold 28,933 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $91.03, for a total value of $2,633,770.99. Following the transaction, the insider owned 2,845 shares of the company’s stock, valued at $258,980.35. The trade was a 91.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 183,564 shares of company stock valued at $16,903,193. Corporate insiders own 15.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on SYRE shares. BTIG Research restated a “buy” rating and issued a $121.00 price objective on shares of Spyre Therapeutics in a research note on Monday, October 19th. Wolfe Research cut Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Spyre Therapeutics from $135.00 to $127.00 and set a “buy” rating on the stock in a report on Wednesday, August 26th. UBS Group initiated coverage on shares of Spyre Therapeutics in a report on Sunday, October 11th. They issued a “buy” rating and a $120.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and set a $123.00 price objective on shares of Spyre Therapeutics in a report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.40.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is centered on engineered antibody therapies designed to provide durable disease control, convenient dosing and improved treatment characteristics.

Spyre’s investigational pipeline includes antibody programs directed at important inflammatory pathways, including interleukin-23 (IL-23) and TL1A.